CN119837879A - 墨蝶呤及其代谢物治疗辐射暴露的用途 - Google Patents

墨蝶呤及其代谢物治疗辐射暴露的用途 Download PDF

Info

Publication number
CN119837879A
CN119837879A CN202411691224.1A CN202411691224A CN119837879A CN 119837879 A CN119837879 A CN 119837879A CN 202411691224 A CN202411691224 A CN 202411691224A CN 119837879 A CN119837879 A CN 119837879A
Authority
CN
China
Prior art keywords
mir
subject
administration
radiation
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411691224.1A
Other languages
English (en)
Chinese (zh)
Inventor
E·梅扎罗马
C·拉本德
R·米克尔森
V·亚科夫列夫
N·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ptc Medical Mp Co
Virginia Commonwealth University
Original Assignee
Ptc Medical Mp Co
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Medical Mp Co, Virginia Commonwealth University filed Critical Ptc Medical Mp Co
Publication of CN119837879A publication Critical patent/CN119837879A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN202411691224.1A 2019-08-05 2020-08-05 墨蝶呤及其代谢物治疗辐射暴露的用途 Pending CN119837879A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
US62/882937 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure
CN202080069308.5A CN114555090B (zh) 2019-08-05 2020-08-05 墨蝶呤及其代谢物治疗辐射暴露的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080069308.5A Division CN114555090B (zh) 2019-08-05 2020-08-05 墨蝶呤及其代谢物治疗辐射暴露的用途

Publications (1)

Publication Number Publication Date
CN119837879A true CN119837879A (zh) 2025-04-18

Family

ID=72148243

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411691224.1A Pending CN119837879A (zh) 2019-08-05 2020-08-05 墨蝶呤及其代谢物治疗辐射暴露的用途
CN202080069308.5A Active CN114555090B (zh) 2019-08-05 2020-08-05 墨蝶呤及其代谢物治疗辐射暴露的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080069308.5A Active CN114555090B (zh) 2019-08-05 2020-08-05 墨蝶呤及其代谢物治疗辐射暴露的用途

Country Status (21)

Country Link
US (1) US20220273661A1 (https=)
EP (2) EP4454712A3 (https=)
JP (2) JP7642611B2 (https=)
CN (2) CN119837879A (https=)
AU (1) AU2020324435B2 (https=)
BR (1) BR112022002029A2 (https=)
CA (1) CA3146477A1 (https=)
DK (1) DK4009978T3 (https=)
ES (1) ES2994060T3 (https=)
FI (1) FI4009978T3 (https=)
HR (1) HRP20241653T1 (https=)
HU (1) HUE069012T2 (https=)
IL (1) IL290321B1 (https=)
LT (1) LT4009978T (https=)
MX (1) MX2022001535A (https=)
PL (1) PL4009978T3 (https=)
PT (1) PT4009978T (https=)
RS (1) RS66096B1 (https=)
SI (1) SI4009978T1 (https=)
SM (1) SMT202500089T1 (https=)
WO (1) WO2021026247A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
EP3801536B1 (en) 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
CN112654356A (zh) 2018-05-30 2021-04-13 Ptc医疗Mp公司 增加四氢生物蝶呤血浆暴露的组合物和方法
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
EP1696877A4 (en) 2003-11-13 2010-06-09 Gen Hospital Corp PROCESS FOR PAIN TREATMENT
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
KR20160068776A (ko) 2013-09-13 2016-06-15 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 방사선 효과의 완화 및 예방을 위한 조성물의 제조 및 용도
WO2016054458A1 (en) 2014-10-02 2016-04-07 Cytosorbents Corporation Use of gastroinstestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物

Also Published As

Publication number Publication date
AU2020324435B2 (en) 2026-03-19
IL290321B1 (en) 2026-04-01
PT4009978T (pt) 2024-11-05
RS66096B1 (sr) 2024-11-29
CA3146477A1 (en) 2021-02-11
EP4009978B1 (en) 2024-09-25
EP4454712A2 (en) 2024-10-30
EP4454712A3 (en) 2025-01-01
SMT202500089T1 (it) 2025-03-12
IL290321A (en) 2022-04-01
MX2022001535A (es) 2022-03-04
PL4009978T3 (pl) 2025-02-24
JP2022543655A (ja) 2022-10-13
FI4009978T3 (fi) 2024-11-01
ES2994060T3 (en) 2025-01-16
AU2020324435A1 (en) 2022-02-24
DK4009978T3 (da) 2024-10-14
US20220273661A1 (en) 2022-09-01
WO2021026247A1 (en) 2021-02-11
LT4009978T (lt) 2024-11-25
HRP20241653T1 (hr) 2025-04-25
JP2025098011A (ja) 2025-07-01
BR112022002029A2 (pt) 2022-06-07
HUE069012T2 (hu) 2025-02-28
SI4009978T1 (sl) 2025-03-31
CN114555090A (zh) 2022-05-27
EP4009978A1 (en) 2022-06-15
CN114555090B (zh) 2024-12-17
JP7642611B2 (ja) 2025-03-10

Similar Documents

Publication Publication Date Title
CN114555090B (zh) 墨蝶呤及其代谢物治疗辐射暴露的用途
JP7042950B2 (ja) ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用
EP3054952B1 (en) Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
US9724349B2 (en) Methods for the treatment of HER2 amplified cancer
CN115605201A (zh) 血管紧张素ii 2型受体激动剂的新用途
US20240067658A1 (en) Benzoxazinone compounds as klk5/7 dual inhibitors
KR20200103056A (ko) 고사이토카인혈증 및 중증 인플루엔자의 치료 또는 예방을 위한 방법 및 화합물
US8957107B2 (en) Method of treating scars and β-catenin-mediated disorders using Nefopam compounds
US20140037548A1 (en) Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors
HK40118407A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
EA052521B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
EA048135B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
CN117379441A (zh) 华蟾素它灵在制备治疗肺纤维化的药物中的应用
HK40075560B (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
HK40075560A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
CN111166756B (zh) 20（S）-人参皂苷-Rg3在逆转胶质瘤细胞对化疗药物的耐药性中的用途
US20230330054A1 (en) Method for preventing or treating lung infection and lung inflammation
JP7854389B2 (ja) Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物
RU2831430C1 (ru) Соединения бензоксазинона в качестве двойных ингибиторов klk5/7
JP7525591B2 (ja) 心機能不全を予測及び処置するための方法
US20220273702A1 (en) Hydrogen sulfide and nitric oxide therapy for covid-19 infection
CN119745894A (zh) 一种通式化合物的用途
TW202310839A (zh) 用於預防或治療纖維化之醫藥組成物
JP2020132626A (ja) サフラナール製剤によるｃｄｃ２５ｂの抑制および阻害
CN109939235A (zh) Fn1基因及其抑制剂在制备抑制乳腺癌转移药物中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination